Further studies are needed to determine IPF therapy based on the delicate balance of the CCL19-CCR7 and CCL21-CCR7 axis, as CCR7 antagonists and specific disease indications are yet to be identified [16]. This evidence concerns the gene CCR7 and idiopathic pulmonary fibrosis.